METASTATIC NEUROENDOCRINE TUMOR
Clinical trials for METASTATIC NEUROENDOCRINE TUMOR explained in plain language.
Never miss a new study
Get alerted when new METASTATIC NEUROENDOCRINE TUMOR trials appear
Sign up with your email to follow new studies for METASTATIC NEUROENDOCRINE TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists test Two-Pronged attack on rare, spreading tumors
Disease control OngoingThis study is testing if adding a new oral drug called triapine to a standard radioactive treatment (Lu-177 dotatate) works better to shrink or slow the growth of advanced neuroendocrine tumors that have spread. It will compare the two-drug combination against the standard single…
Matched conditions: METASTATIC NEUROENDOCRINE TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Scientists test Two-Pronged attack on rare digestive cancers
Disease control OngoingThis early-stage study is testing a new combination of two drugs for people with advanced neuroendocrine tumors that have spread. The goal is to find the safest and most effective dose by giving patients an oral drug (triapine) alongside a targeted radiation therapy (lutetium Lu …
Matched conditions: METASTATIC NEUROENDOCRINE TUMOR
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug trial aims to halt rare Cancer's spread
Disease control OngoingThis study is testing whether a drug called pazopanib can slow or stop the growth of carcinoid tumors that are getting worse. It compares pazopanib against a placebo (inactive pill) in 171 patients whose tumors have progressed. The main goal is to see if the drug helps patients l…
Matched conditions: METASTATIC NEUROENDOCRINE TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 17, 2026 13:08 UTC